Objetivo Sublimity Therapeutics has developed an innovative product, ST-0529, to treat patients with moderate-severe Ulcerative Colitis, a disease that affects 1 million patients in Europe. ST-0529 is enabled using Sublimity Therapeutics ’s proprietary SmPill® nanoemulsion-based technology to target a known and powerful drug, Cyclosporine, directly to inflamed colons. In Phase II human studies, ST-0529 was proven to be effective and safe. ST-0529, an oral product, will compete with injected, expensive drugs that have a risk of serious side effects.Successful development and commercialisation of ST-0529 will pivot on development of a stable ST-0529 product and a positive outcome of the clinical trials. Overall, the project will involve leading EU-based specialist SME, technology and equipment suppliers as well as a number of knowledge providers. The budget is €1.6M and will be completed in 58 months. Successful completion of this project will retain and enhance intellectual property and know-how in Sublimity Therapeutics, increase long term high skill jobs. In parallel, the project will unlock the value inherent not only of ST-0529, but also the underlying SmPill® technology platform. Furthermore, the project will increase the probability of overall company success and increase significantly the NPV to more than €500M. Ámbito científico engineering and technologymechanical engineeringmanufacturing engineeringmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseaseengineering and technologychemical engineering Programa(s) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Tema(s) NMP-25-2014 - Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs Convocatoria de propuestas H2020-SMEInst-2014-2015 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-2-2014 Régimen de financiación SME-2 - SME instrument phase 2 Coordinador SUBLIMITY THERAPEUTICS LIMITED Aportación neta de la UEn € 1 600 000,00 Dirección INVENT CENTRE DUBLIN CITY UNIVERSITY 9 DUBLIN Irlanda Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región Ireland Eastern and Midland Dublin Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 2 307 500,00
